CHA2DS2-VASc Score: Difference between revisions
(New page: {{SI}} {{CMG}} {{EJ}} ==Overview== The '''CHA<sub>2</sub>DS<sub>2</sub>-VASc score''' predicts clinical risk of stroke and thromboembolism in atrial fibrillation<ref>[http://www.ncb...) |
|||
| Line 38: | Line 38: | ||
|----- | |----- | ||
|} | |} | ||
==Anticoagulation based on the CHA<sub>2</sub>DS<sub>2</sub>-VASc score == | |||
The following treatment strategies are recommended in the table below entitled Anticoagulation based on the CHADS2 score:<ref name="pmid15477396 " /><ref name=Gage2001 /> | |||
{| class="wikitable" style = "float: right; margin-left:15px; text-align:center" | |||
|- | |||
! Score | |||
! Risk | |||
! Anticoagulation Therapy | |||
! Considerations | |||
|- | |||
| '''0''' | |||
| Low | |||
| [[Aspirin]] | |||
| Aspirin daily | |||
|- | |||
| '''1''' | |||
| Moderate | |||
| Aspirin or Warfarin | |||
| Aspirin daily or [[International normalized ratio|INR]] to 2.0-3.0, depending on factors such as patient preference | |||
|- | |||
| '''2 or greater''' | |||
| Moderate or High | |||
| [[Warfarin]] | |||
| [[International normalized ratio|INR]] to 2.0-3.0, unless contraindicated (e.g. clinically significant GI bleeding, inability to obtain regular INR screening) | |||
|} | |||
==Assessment of Bleeding Risk with Anticoagulation== | |||
The decision to anticoagulate a patient should also be based upon an assessment of the risk of bleeding using a score such as the [[HAS-BLED score]]. | |||
==REFERENCES== | ==REFERENCES== | ||
Revision as of 19:01, 26 November 2010
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
The CHA2DS2-VASc score predicts clinical risk of stroke and thromboembolism in atrial fibrillation[1].
| Feature | Score if present |
|---|---|
| Congestive Heart Failure | 1 |
| Hypertension | 1 |
| Age ≥ 75 years | 2 |
| Age between 65 and 74 years | 1 |
| Stroke/TIA/TE | 2 |
| Vascular disease (previous MI, peripheral arterial disease or aortic plaque) | 1 |
| Diabetes mellitus | 1 |
| Female | 1 |
Anticoagulation based on the CHA2DS2-VASc score
The following treatment strategies are recommended in the table below entitled Anticoagulation based on the CHADS2 score:[2][3]
| Score | Risk | Anticoagulation Therapy | Considerations |
|---|---|---|---|
| 0 | Low | Aspirin | Aspirin daily |
| 1 | Moderate | Aspirin or Warfarin | Aspirin daily or INR to 2.0-3.0, depending on factors such as patient preference |
| 2 or greater | Moderate or High | Warfarin | INR to 2.0-3.0, unless contraindicated (e.g. clinically significant GI bleeding, inability to obtain regular INR screening) |
Assessment of Bleeding Risk with Anticoagulation
The decision to anticoagulate a patient should also be based upon an assessment of the risk of bleeding using a score such as the HAS-BLED score.
REFERENCES
- ↑ Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb; 137(2):263-72.(Link to article – subscription may be required.)
- ↑
- ↑